Company news
PMV Pharmaceuticals, Inc. news in 2022
PMV Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 7, 2022
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
November 3, 2022
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 8, 2022
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
July 17, 2022
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
June 6, 2022
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2022
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
May 9, 2022
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 28, 2022
PMV Pharma Announces Changes to its Board of Directors
January 5, 2022
Decks in 2022
- ASCO 2022 PC14586 Investor Event
Conference · 32 slides · Jun 8, 2022
- ASCO 2022
Conference · 16 slides · June 2022